FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMayne Pharma Group Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MYX.AX
Mayne Pharma Group Limited Stock AnalysisComprehensive stock analysis for Mayne Pharma Group Limited (MYX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMYX.AX
MYX.AX
Mayne Pharma Group Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MYX.AX
  1. Home
  2. Stocks
  3. Mayne Pharma Group Limited

Mayne Pharma Group Limited

🇦🇺MYX.AX•ASX

Mayne Pharma Group Limited

🇦🇺MYX.AX•ASX
P/E ratio
19.55

Your view on MYX.AX

P/E
19.55
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Mayne Pharma Group Limited

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Aaron Gray
Headquarters
1538 Main North Road, Salisbury South, SA, AU
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Aaron Gray
Headquarters
1538 Main North Road, Salisbury South, SA, AU
Description

Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia.

The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products.

Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients.

Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases.

Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Mayne Pharma Group Limited. Starting points for Mayne Pharma Group Limited: P/E 19.5, EPS AUD 0.30, beta 1.00 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Mayne Pharma Group Limited. Mayne Pharma Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Mayne Pharma Group Limited. Trailing twelve-month EPS for Mayne Pharma Group Limited stands at AUD 0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2014Next quarterJun 2021This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.03AUD 0.02−AUD 0.36−AUD 0.22
Lowest estimateAUD 0.03AUD 0.01−AUD 0.48−AUD 0.22
Highest estimateAUD 0.03AUD 0.05−AUD 0.25−AUD 0.22
Number of analysts21022
A year ago——AUD 0.211—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2014Next quarterJun 2021This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 66.58MAUD 546.78MAUD 375.90MAUD 322.73M
Lowest estimateAUD 63.63MAUD 487.22MAUD 366.31MAUD 305.70M
Highest estimateAUD 66.91MAUD 624.10MAUD 380.79MAUD 336.30M
Number of analysts2933
A year ago——AUD 383.68M—
Growth vs a year ago——−2.0%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Mayne Pharma Group Limited. Mayne Pharma Group Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MYX.AX19 companies · 8 funds
Compare MYX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AVE.AXAvecho Biotechnology LimitedHealthcareBiotechnology—
CAN.AXCann Group LimitedHealthcareDrug Manufacturers - Specialty & Generic—
EPN.AXEpsilon Healthcare LimitedHealthcareDrug Manufacturers - Specialty & Generic—
EXL.AXElixinol Wellness LimitedHealthcareDrug Manufacturers - Specialty & Generic—
IDT.AXIDT Australia LimitedHealthcareDrug Manufacturers - Specialty & Generic—
LGP.AXLittle Green Pharma LtdHealthcareDrug Manufacturers - Specialty & Generic—
RGT.AXArgent BioPharma LimitedHealthcareDrug Manufacturers - Specialty & Generic—
More Medical - Pharmaceuticals companies
TickerTypeCompanySectorExchangeMkt cap
COSMCosmos Health Inc.HealthcareNASDAQ$14.8M
CSCI.TOCOSCIENS Biopharma Inc.HealthcareTSX$8.6M
CSCIFCOSCIENS Biopharma Inc.HealthcareOTC$6.0M
CSMYFCOSMOS Pharmaceutical CorporationHealthcareOTC$3.8B
CTORCitius Oncology, Inc.HealthcareNASDAQ$51.8M
CTTHCTT Pharmaceutical Holdings, Inc.HealthcareOTC$1.9M
CUVLClinuvel Pharmaceuticals Ltd.HealthcareNASDAQ$245.1M
CXBSCorix Bioscience, Inc.HealthcareOTC$2,734
CYBN.NECybin Inc.HealthcareNEO—
DECNDecision Diagnostics Corp.HealthcareOTC$35,450
DOSEFDoseology Sciences Inc.HealthcareOTC$1.7M
EBM.VEastwood Bio-Medical Canada Inc.HealthcareTSXV$44.1M
ETFs holding Mayne Pharma Group Limited
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.00%
VEAVanguard FTSE Developed Markets ETF$231.6B in assets0.00%
VSSVanguard FTSE All-World ex-US Small-Cap ETF$11.6B in assets0.00%
AVDVAvantis International Small Cap Value ETF$19.2B in assets—
DFISDimensional - International Small Cap ETF$5.8B in assets0.00%
DFICDimensional - International Core Equity 2 ETF$15.4B in assets0.00%
VIU.TOVanguard FTSE Developed All Cap ex North America Index ETF$11.4B in assets0.00%
VSGXVanguard ESG International Stock ETF$6.7B in assets0.00%

Largest holders first, then the funds most concentrated in MYX.AX.

Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Mayne Pharma Group Limited. Coverage tracks Mayne Pharma Group Limited within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Mayne Pharma Group Limited.

MYX.AX AnalysisGood
Past
2
Growth
5
Health
5
Profit
2
Value
2